{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:30Z","timestamp":1789726290015,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004421","name":"World Bank","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004421","id-type":"DOI","asserted-by":"publisher"}]},{"name":"East African Public Health Laboratory Networking Project","award":["P111556"],"award-info":[{"award-number":["P111556"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Uganda, artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DHA-PQ) showed excellent treatment efficacy for uncomplicated malaria in prior trials. Because the frequency of resistance to artemisinins and piperaquine is increasing in Southeast Asia and the prevalence of Plasmodium falciparum polymorphisms associated with resistance has changed, we reassessed treatment efficacies at 3 sites in Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For this randomized, single-blinded clinical trial, children aged 6\u201359 months with uncomplicated falciparum malaria were assigned treatment with AL or DHA-PQ and followed for 42 days. Primary end points were risks of recurrent parasitemia, either unadjusted or adjusted to distinguish recrudescence from new infection. We assessed selection by study regimens of relevant P. falciparum genetic polymorphisms associated with drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 599 patients enrolled, 578 completed follow-up. There were no early treatment failures. The risk of recurrent parasitemia was lower with DHA-PQ as compared to AL at all 3 sites at 42 days (26.0% vs 47.0%; P &amp;lt; .001). Recrudescent infections were uncommon in both the DHA-PQ and AL arms (1.1% and 2.2%, respectively; P = .25). Neither regimen selected for pfcrt or pfmdr1 polymorphisms associated with drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AL and DHA-PQ remain effective for the treatment of malaria in Uganda. Neither regimen selected for genetic polymorphisms associated with drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>ISRCTN15793046.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiy637","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T16:12:54Z","timestamp":1541088774000},"page":"1112-1120","source":"Crossref","is-referenced-by-count":47,"title":["Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children"],"prefix":"10.1093","volume":"219","author":[{"given":"Adoke","family":"Yeka","sequence":"first","affiliation":[{"name":"School of Public Health, Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Wallender","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Mulebeke","sequence":"additional","affiliation":[{"name":"School of Public Health, Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afizi","family":"Kibuuka","sequence":"additional","affiliation":[{"name":"School of Public Health, Makerere University College of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Kigozi","sequence":"additional","affiliation":[{"name":"Malaria Action Programme for Districts, Malaria Consortium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agaba","family":"Bosco","sequence":"additional","affiliation":[{"name":"National Malaria Control Program, Ministry of Health, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kyambadde","sequence":"additional","affiliation":[{"name":"National Malaria Control Program, Ministry of Health, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Opigo","sequence":"additional","affiliation":[{"name":"National Malaria Control Program, Ministry of Health, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"Kalyesubula","sequence":"additional","affiliation":[{"name":"East African Public Health Laboratories Networking Project, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Senzoga","sequence":"additional","affiliation":[{"name":"East African Public Health Laboratories Networking Project, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Vinden","sequence":"additional","affiliation":[{"name":"School of Public Health, University of California, Berkeley"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"2026041420074121200_CIT0001","first-page":"CD010927","article-title":"Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria","author":"Zani","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026041420074121200_CIT0002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14656566.2013.771167","article-title":"Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa","volume":"14","author":"Ogutu","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"2026041420074121200_CIT0003","doi-asserted-by":"crossref","DOI":"10.30875\/50d27d62-en","volume-title":"World malaria report 2017","author":"World Health Organization (WHO)","year":"2017"},{"key":"2026041420074121200_CIT0004","doi-asserted-by":"crossref","first-page":"e64299","DOI":"10.1371\/journal.pone.0064299","article-title":"The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008\u20132011","volume":"8","author":"Eyase","year":"2013","journal-title":"PLoS One"},{"key":"2026041420074121200_CIT0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1475-2875-12-103","article-title":"Temporal trends of molecular markers associated with artemether-lumefantrine tolerance\/resistance in Bagamoyo district, Tanzania","volume":"12","author":"Malmberg","year":"2013","journal-title":"Malar J"},{"key":"2026041420074121200_CIT0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpddr.2015.05.005","article-title":"Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya","volume":"5","author":"Achieng","year":"2015","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2026041420074121200_CIT0007","first-page":"631","article-title":"Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda","volume":"215","author":"Tumwebaze","year":"2017","journal-title":"J Infect Dis"},{"key":"2026041420074121200_CIT0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01516-17","article-title":"Changing antimalarial drug sensitivities in Uganda","volume":"61","author":"Rasmussen","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041420074121200_CIT0009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4269\/ajtmh.13-0647","article-title":"Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda","volume":"91","author":"Mbogo","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2026041420074121200_CIT0010","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.05141-14","article-title":"Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children","volume":"59","author":"Tumwebaze","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041420074121200_CIT0011","doi-asserted-by":"crossref","first-page":"ofw229","DOI":"10.1093\/ofid\/ofw229","article-title":"Artemether-lumefantrine and dihydroartemisinin-piperaquine exert inverse selective pressure on plasmodium falciparum drug sensitivity-associated haplotypes in Uganda","volume":"4","author":"Taylor","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2026041420074121200_CIT0012","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/infdis\/jiu141","article-title":"Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children","volume":"210","author":"Conrad","year":"2014","journal-title":"J Infect Dis"},{"key":"2026041420074121200_CIT0013","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/jiv551","article-title":"Artesunate\/Amodiaquine Versus Artemether\/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial","volume":"213","author":"Yeka","year":"2016","journal-title":"J Infect Dis"},{"key":"2026041420074121200_CIT0014","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N Engl J Med"},{"key":"2026041420074121200_CIT0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","article-title":"Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study","volume":"16","author":"Amaratunga","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026041420074121200_CIT0016","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2026041420074121200_CIT0017","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.actatropica.2011.03.004","article-title":"Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts","volume":"121","author":"Yeka","year":"2012","journal-title":"Acta Trop"},{"key":"2026041420074121200_CIT0018","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"World Health Organization (WHO)","year":"2009"},{"key":"2026041420074121200_CIT0019","volume-title":"Guidelines for the treatment of malaria","author":"World Health Organization (WHO)","year":"2015","edition":"3rd ed"},{"key":"2026041420074121200_CIT0020","volume-title":"Pocket book of hospital care for children: guidelines for management of common childhood illnesses","author":"World Health Organization (WHO)","year":"2013"},{"key":"2026041420074121200_CIT0021","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1001\/jama.297.20.2210","article-title":"Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial","volume":"297","author":"Dorsey","year":"2007","journal-title":"JAMA"},{"key":"2026041420074121200_CIT0022","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4269\/ajtmh.2006.75.836","article-title":"Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections","volume":"75","author":"Greenhouse","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"2026041420074121200_CIT0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0166-6851(93)90077-B","article-title":"High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction","volume":"61","author":"Snounou","year":"1993","journal-title":"Mol Biochem Parasitol"},{"key":"2026041420074121200_CIT0024","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/JCM.00904-13","article-title":"Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of Plasmodium falciparum","volume":"51","author":"LeClair","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2026041420074121200_CIT0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/1475-2875-10-339","article-title":"Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator","volume":"10","author":"Flegg","year":"2011","journal-title":"Malar J"},{"key":"2026041420074121200_CIT0026","author":"Worldwide Antimalarial Resistance Network (WWARN)"},{"key":"2026041420074121200_CIT0027","doi-asserted-by":"crossref","first-page":"e2390","DOI":"10.1371\/journal.pone.0002390","article-title":"Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda","volume":"3","author":"Yeka","year":"2008","journal-title":"PLoS One"},{"key":"2026041420074121200_CIT0028","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1371\/journal.pctr.0020020","article-title":"Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial","volume":"2","author":"Kamya","year":"2007","journal-title":"PLoS Clin Trials"},{"key":"2026041420074121200_CIT0029","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","author":"West African Network for Clinical Trials of Antimalarial D","year":"2018","journal-title":"Lancet"},{"key":"2026041420074121200_CIT0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12936-015-0874-1","article-title":"Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis","volume":"14","author":"Abdulla","year":"2015","journal-title":"Malar J"},{"key":"2026041420074121200_CIT0031","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1128\/AAC.00921-15","article-title":"Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular Assays","volume":"59","author":"Cooper","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041420074121200_CIT0032","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/cid\/ciu353","article-title":"Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria","volume":"59","author":"Wanzira","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026041420074121200_CIT0033","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","article-title":"Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study","volume":"15","author":"Spring","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026041420074121200_CIT0034","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/AAC.00955-07","article-title":"Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand","volume":"52","author":"Tarning","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026041420074121200_CIT0035","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1128\/AAC.00920-16","article-title":"Intermittent preventive treatment with dihydroartemisinin-piperaquine in Ugandan schoolchildren selects for Plasmodium falciparum transporter polymorphisms that modify drug sensitivity","volume":"60","author":"Nankabirwa","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/219\/7\/1112\/36160687\/jiy637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/219\/7\/1112\/36160687\/jiy637.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:15:08Z","timestamp":1776212108000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/219\/7\/1112\/5174239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,11,12]]},"published-print":{"date-parts":[[2019,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy637","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4,1]]},"published":{"date-parts":[[2018,11,12]]}}}